TUMOR DRUG RESPONSE TESTING - A LIVE CHEMORESPONSE MARKER
Identify effective treatments for your GYN cancer patients
Treatment guidelines are a tool to help direct therapy for many types of cancer, but there are times when these guidelines fall short. What do you do when patients are refractory to initial treatment, have rare tumor types or tumors with no established protocol, or suffer from recurrent cancer? While not intended to replace standard-of-care, a drug response marker, such as ChemoFX ( now known as Tumor Drug Response Testing - TDRT) can be valuable in helping you identify treatment choices that are more likely to be effective for your particular cancer patient.
Tumor Drug Response Testing (formerly ChemoFx) is a fresh tissue platform that uses the patients own live tumor cells to help physicians identify effective treatment options for each gynecologic cancer patient
Tumor Drug Response Testing (formerly ChemoFX) was created to help you rule out chemotherapies that don't work and focus on the ones that are more likely to work—reducing risk to your patient.
Ineffective therapies can lead to:
Increased side effects
Development of cross-resistance
Decreased efficacy of future treatments
Decreased quality of life
Tumor Drug Response Testing (ChemoFX) can be used in
Determining platinum sensitivity and resistance
Selecting the most effective treatments
Categorizing treatments for potential effectiveness
Personalized treatment plan
No two cancer patients are the same, and neither is their response to chemotherapy. With Tumor Drug Response Testing (formerly ChemoFX), you can personalize your patient's treatment plan by testing multiple single or combination chemotherapies in the lab before choosing one for your cancer patient. Depending on the type of cancer and your patient's needs, you may also want to test various biologics.
Select up to 12 drugs or drug combinations, and use your experience and knowledge of each patient to choose a standard panel or design a custom panel. Choosing agents from different drug classes may help you evaluate alternative treatment options for your patients.
Demonstrated clinical utility as a prognostic and predictive drug response marker
ChemoFx is associated with a 50% improvement in progression free survival and a 14 month improvement in overall survival when patients receive a sensitive therapy.
Rutherford et al.
Patients treated with a sensitive agent identified by ChemoFx lived 2.5x longer than patients treated with a resistant agent.
Herzog et al.
ChemoFx identifies potentially effective treatments for the majority (59%) of Platinum Resistant Patients.
Krivak et al.
Requires a small sample
In addition to helping protect your patients from ineffective therapies, you also want to spare them from any unnecessary procedures. Tumor Drug Response Testing can help you accomplish both. The test requires a small tissue sample from surgery. This small sample size allows for less invasive procedures at multiple stages of care. Because cells grow and cycle in culture, Tumor Drug Response Testing ensures enrichment of relevant malignant cells for testing.
Look inside our live-cell platform
Learn about the Tumor Drug Response Testing (formerly ChemoFx) process in this video from within the Helomics lab in Pittsburgh.
The Final Report
The ChemoFx (now Tumor Drug Response Testing) final report has been specifically designed with physician input to clearly and concisely deliver your patient’s test results.
Provides information on chemo-sensitivity of available therapies
Provides results of patient's individual tumor cell analysis
Informs treatment strategy and selection
No delay in treatment
Results are provided within a standard time frame for initiating therapy, enabling you to make critical decisions without delaying treatment. Your patients can get on with their therapy—and more importantly, their lives.
Specifically, the turn-around-time for the ChemoFx test is 28-35 days after the receipt of tissue and all required paperwork, depending on the growth profile of the sample.
Please click the button below to read about the simple process of ordering test kits to be sent to your facility and the required paperwork from you and your patient.
1. A Prospective Study Evaluating the Clinical Relevance of a Chemoresponse Assay for Treatment of Patients with Persistent or Recurrent Ovarian Cancer; Rutherford T, Orr Jr. J, Grendys Jr. E, Edwards R, Krivak T, Holloway R, Moore RG, Puls L, Tillmans T, Burrell M, Hosford S, Kamat AA, Modesitt S, Schin JC, Tian C, Gabrin MJ, Brower SL, Coleman RL, Herzog TJ - Gynecologic Oncology 2013
2. Chemosensitivity Testing with ChemoFx and Overall Survival in Primary Ovarian Cancer; Herzog TJ, Fader AN, Fensterer JE, Gallion HH, Krivak TC, Coleman RL - American Journal of Obstetrics and Gynecology 2010
3. A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer; Krivak TC, Lele S, Richard S, Alvarez Secord A, Leath III CA, Brower SL, Tian C, Moore RG - American Journal of Obstetrics and Gynecology 2014